search
Back to results

Rapid Research in Diagnostics Development for TB Network (R2D2TB Network)

Primary Purpose

Tuberculosis

Status
Recruiting
Phase
Not Applicable
Locations
International
Study Type
Interventional
Intervention
Novel mycobacterial culture techniques
Novel sputum smear microscopy techniques
Sputum-based molecular assays
Tongue swab-based molecular assays
Urine LAM assays
Blood-based host immune response assays
Breath-based assays
Artificial intelligence-based digital health tools
Phage-based assays
Cartridge-based molecular assays for detecting drug resistance
Sequencing-based assays for detecting drug resistance
Sponsored by
University of California, San Francisco
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Tuberculosis focused on measuring Tuberculosis, Diagnostics, Global Health

Eligibility Criteria

12 Years - undefined (Child, Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • For evaluation of TB triage/diagnostic test: We will include adult outpatients (age ≥18 years) with either a cough ≥2 weeks' duration or a known TB risk factor (HIV or diabetes).
  • For evaluation of rDST tests: We will include adults (age ≥18 years) who are positive for TB and RIF resistance according to routine diagnostic testing (based typically on Xpert MTB/RIF, Xpert MTB/RIF Ultra, or Hain MTBDRplus).
  • For the usability assessment: We will include health workers at each clinical site who are 1) aged ≥18 years and 2) involved in routine TB testing (collecting specimens for or performing TB tests).

Exclusion Criteria:

  • For evaluation of TB triage/diagnostic tests: We will exclude patients who: completed latent or active TB treatment within the past 12 months (to increase TB prevalence and reduce false-positive results, respectively); have taken any medication with anti-mycobacterial activity (including fluoroquinolones) for any reason, within 2 weeks of study entry (to reduce false-negatives); reside >20km from the study site or are unwilling to return for follow-up visits; or are unwilling to provide informed consent
  • For evaluation of rDST tests: We will exclude patients who: have negative or contaminated results on all baseline (i.e., enrollment) sputum cultures; are unable to provide at least two sputum specimens of 3 mL each within one day of enrollment; or are unable or unwilling to provide informed consent.
  • For the usability assessment: We will exclude staff who are unwilling to provide informed consent.

Sites / Locations

  • National Center for Tuberculosis and Lung DiseasesRecruiting
  • Chitoor (Christian Medical College satellite campus)Recruiting
  • Christian Medical College CMC Pulmonary Outpatient DepartmentRecruiting
  • Primary care clinics (Shalom/LCC, CHAD)Recruiting
  • De La Salle Medical and Health Sciences InstituteRecruiting
  • Brooklyn Chest HospitalRecruiting
  • Khayelitsha District Health CenterRecruiting
  • Kraaifontein Community Health ClinicRecruiting
  • Scottsdene primary care clinicRecruiting
  • Wallacedene primary care clinicRecruiting
  • Kisenyi Health CenterRecruiting
  • Mulago Outpatient DepartmentRecruiting
  • Hanoi Lung Hospital, Outpatient departmentsRecruiting
  • National Lung Hospital, Outpatient departmentsRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

Evaluation of various novel TB triage and diagnostic tests.

Evaluation of novel rDST assays

Arm Description

For the novel TB triage and diagnostic tests, the investigators will conduct large-scale evaluation of design-locked tests in a cohort of adults with presumed TB, with nested feasibility/pilot studies of early and late prototype tests. The investigators aim to enroll 300-450 participants per year at each of five enrollment sites for evaluation of various novel TB triage and diagnostic tests and 50 health workers to assess test usability.

Clinicians at participating sites will be asked to refer adult patients with rifampin-resistance identified by routine molecular testing. The investigators aim to enroll 100-200 patients per year at each of three enrollment sites for evaluation of novel rDST assays.

Outcomes

Primary Outcome Measures

Sensitivity
Number of positive results for a given index test/(Total positive + negative results for a given index test) among patients with TB using the microbiological reference standard
Specificity
Number of negative results for a given index test/(Total positive + negative results for a given index test) among patients without TB using the microbiological reference standard

Secondary Outcome Measures

Full Information

First Posted
June 7, 2021
Last Updated
June 27, 2023
Sponsor
University of California, San Francisco
Collaborators
University Hospital Heidelberg, Christian Medical College, Vellore, India, Vietnam National Lung Hospital, De La Salle University Medical Center, University of Stellenbosch, Makerere University, Johns Hopkins Bloomberg School of Public Health, Harvard Medical School (HMS and HSDM), Stanford University, Foundation for Innovative New Diagnostics, Switzerland, Socios En Salud Sucursal, Peru, Federal University of Mato Grosso, Medical Research Council, National Center for Tuberculosis and Lung Disease, Tbilisi, Georgia, Centre for Infectious Disease Research in Zambia, National Institute of Allergy and Infectious Diseases (NIAID)
search

1. Study Identification

Unique Protocol Identification Number
NCT04923958
Brief Title
Rapid Research in Diagnostics Development for TB Network
Acronym
R2D2TB Network
Official Title
Rapid Research in Diagnostics Development for TB Network (R2D2 TB Network) Study
Study Type
Interventional

2. Study Status

Record Verification Date
June 2023
Overall Recruitment Status
Recruiting
Study Start Date
April 14, 2021 (Actual)
Primary Completion Date
May 31, 2025 (Anticipated)
Study Completion Date
May 31, 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of California, San Francisco
Collaborators
University Hospital Heidelberg, Christian Medical College, Vellore, India, Vietnam National Lung Hospital, De La Salle University Medical Center, University of Stellenbosch, Makerere University, Johns Hopkins Bloomberg School of Public Health, Harvard Medical School (HMS and HSDM), Stanford University, Foundation for Innovative New Diagnostics, Switzerland, Socios En Salud Sucursal, Peru, Federal University of Mato Grosso, Medical Research Council, National Center for Tuberculosis and Lung Disease, Tbilisi, Georgia, Centre for Infectious Disease Research in Zambia, National Institute of Allergy and Infectious Diseases (NIAID)

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Device Product Not Approved or Cleared by U.S. FDA
Yes
Product Manufactured in and Exported from the U.S.
Yes
Data Monitoring Committee
No

5. Study Description

Brief Summary
To reduce the burden of TB worldwide through more accurate, faster, simpler, and less expensive diagnosis of TB Every year, more than 3 million people with TB remain undiagnosed and 1 million die. Better diagnostics are essential to reducing the enormous burden of TB worldwide. The Rapid Research in Diagnostics Development for TB Network (R2D2 TB Network) brings together experts in TB care, technology assessment, diagnostics development, laboratory medicine, epidemiology, health economics and mathematical modeling with highly experienced clinical study sites in 10 countries
Detailed Description
The Rapid Research in Diagnostics Development for TB Network (R2D2 TB Network) study seeks to identify and rigorously assess promising early stage tuberculosis (TB) triage, diagnostic and drug resistance tests (hereafter referred to as "novel tests") in clinical studies conducted in settings of intended use. Rapid diagnosis, identification of drug resistance and effective treatment are critical for improving patient outcomes and reducing TB transmission. However, analysis of care cascades and prevalence surveys indicate that 40-60% of patients with TB are not initiated on effective treatment.1,2 The different types of tests required to reduce this "diagnostic gap" have been described in the form of target product profiles (TPPs). The highest- priority TPPs are for: 1) a point-of-care, non-sputum biomarker-based test to facilitate rapid TB diagnosis using easily accessible samples (a biomarker-based diagnostic test) and 2) a simple, low-cost test that can be used by front-line health workers to rule-out TB (a triage test). The R2D2 TB Network study will evaluate the sensitivity and specificity of novel triage and diagnostic tests against a reference standard including sputum Xpert® MTB/RIF (Mycobacterium tuberculosis/Rifampin) Ultra and sputum mycobacterial culture. The sensitivity and specificity of rapid drug susceptibility tests (rDST) will be compared against a reference standard including culture-based phenotypic DST and whole genome sequencing (WGS) of mycobacterial DNA. In addition, the usability of novel tests will be assessed through direct observations and surveys of routine health workers.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Tuberculosis
Keywords
Tuberculosis, Diagnostics, Global Health

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
6050 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Evaluation of various novel TB triage and diagnostic tests.
Arm Type
Experimental
Arm Description
For the novel TB triage and diagnostic tests, the investigators will conduct large-scale evaluation of design-locked tests in a cohort of adults with presumed TB, with nested feasibility/pilot studies of early and late prototype tests. The investigators aim to enroll 300-450 participants per year at each of five enrollment sites for evaluation of various novel TB triage and diagnostic tests and 50 health workers to assess test usability.
Arm Title
Evaluation of novel rDST assays
Arm Type
Experimental
Arm Description
Clinicians at participating sites will be asked to refer adult patients with rifampin-resistance identified by routine molecular testing. The investigators aim to enroll 100-200 patients per year at each of three enrollment sites for evaluation of novel rDST assays.
Intervention Type
Diagnostic Test
Intervention Name(s)
Novel mycobacterial culture techniques
Intervention Description
We will evaluate tests intended to make culture more sensitive, faster, and have less contamination.
Intervention Type
Diagnostic Test
Intervention Name(s)
Novel sputum smear microscopy techniques
Intervention Description
We will evaluate new staining techniques or visualization methods to increase the sensitivity of smear microscopy.
Intervention Type
Diagnostic Test
Intervention Name(s)
Sputum-based molecular assays
Intervention Description
We will evaluate semi-automated or automated molecular assays intended for use at near point of care or point of care.
Intervention Type
Diagnostic Test
Intervention Name(s)
Tongue swab-based molecular assays
Intervention Description
We will evaluate semi-automated or automated molecular assays intended for use at near point of care or point of care.
Intervention Type
Diagnostic Test
Intervention Name(s)
Urine LAM assays
Intervention Description
We will evaluate urine LAM assays incorporating techniques such as analyte concentration, higher sensitivity or specificity antibodies, or enhanced visualization to improve LAM detection.
Intervention Type
Diagnostic Test
Intervention Name(s)
Blood-based host immune response assays
Intervention Description
We will evaluate assays measuring host immune response parameters intended for use at near point of care or point of care.
Intervention Type
Diagnostic Test
Intervention Name(s)
Breath-based assays
Intervention Description
We will evaluate assays assessing volatile organic compounds or exhaled breath condensate for near point of care of point of care detection of TB.
Intervention Type
Diagnostic Test
Intervention Name(s)
Artificial intelligence-based digital health tools
Intervention Description
We will evaluate AI-based algorithms evaluating images (chest x-ray, ultrasound) or sounds (cough sounds, lung sounds) including an Infrasound-to-ultrasound e-stethoscope (Level 42 AI, USA).
Intervention Type
Diagnostic Test
Intervention Name(s)
Phage-based assays
Intervention Description
We will evaluate assays using phages to lyse mycobacterial cells for detection of DNA or antigens.
Intervention Type
Diagnostic Test
Intervention Name(s)
Cartridge-based molecular assays for detecting drug resistance
Intervention Description
We will evaluate semi-automated or automated molecular assays intended for use at near point of care or point of care.
Intervention Type
Diagnostic Test
Intervention Name(s)
Sequencing-based assays for detecting drug resistance
Intervention Description
We will evaluate targeted and whole genome sequencing assays.
Primary Outcome Measure Information:
Title
Sensitivity
Description
Number of positive results for a given index test/(Total positive + negative results for a given index test) among patients with TB using the microbiological reference standard
Time Frame
2 years
Title
Specificity
Description
Number of negative results for a given index test/(Total positive + negative results for a given index test) among patients without TB using the microbiological reference standard
Time Frame
2 years

10. Eligibility

Sex
All
Minimum Age & Unit of Time
12 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Novel TB triage and diagnostic tests: We will include non-hospitalized adults (age ≥ 12 years) with either 1) cough ≥2 weeks' duration, a commonly accepted criterion for identifying people with presumed pulmonary TB (to facilitate standardization across sites and comparison of test performance across sub-groups or 2) risk factors for which TB screening is recommended (HIV infection, self-reported close contact, history of mining work). People with risk factors will be included if they screen positive for TB based on WHO-recommended screening tools as specified below: Positive TB screening definitions by risk factor: PLHIV (Risk Factor), CRP >5 mg/dL OR abnormal CXR (Positive TB screening definition) Self-reported Close Contact (Risk Factor), abnormal CXR (Positive TB screening definition) History of mining work (Risk Factor), abnormal CXR (Positive TB screening definition) We will exclude people who: completed latent or active TB treatment within the past 12 months (to increase TB prevalence and reduce false-positive results, respectively); have taken any medication with anti-mycobacterial activity (including fluoroquinolones) for any reason, within 2 weeks of study entry (to reduce false-negatives); reside >20km from the study site or are unwilling to return for follow-up visits; or are unwilling to provide informed consent Novel TB rDST assays: We will include adults (age ≥12 years) who are positive for TB and RIF resistance according to routine diagnostic testing (based typically on Xpert MTB/RIF, Xpert MTB/RIF Ultra, or Hain MTBDRplus). We will exclude people who: have negative or contaminated results on all baseline (i.e., enrollment) sputum cultures are unable to provide at least two sputum specimens of 3 mL each within one day of enrollment are unable or unwilling to provide informed consent Assessment of the usability of novel TB tests: We will include health workers at each clinical site who are 1) aged ≥18 years and 2) involved in routine TB testing (collecting specimens for or performing TB tests). We will exclude staff who are unwilling to provide informed consent.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Adithya Cattamanchi, MD
Phone
+1-415-206-5489
Email
adithya.cattamanchi@ucsf.edu
First Name & Middle Initial & Last Name or Official Title & Degree
Catherine Cook, MPH
Phone
603-988-9940
Email
catherine.cook@ucsf.edu
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Adithya Cattamanchi, MD
Organizational Affiliation
University of California, San Francisco
Official's Role
Principal Investigator
Facility Information:
Facility Name
National Center for Tuberculosis and Lung Diseases
City
Tbilisi
Country
Georgia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Nestani Tukvadze
Email
Nestan Tukvadze <marikushane@yahoo.com>
Facility Name
Chitoor (Christian Medical College satellite campus)
City
Vellore
Country
India
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
DJ Christopher
Email
djchris@cmcvellore.ac.in
Facility Name
Christian Medical College CMC Pulmonary Outpatient Department
City
Vellore
Country
India
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
DJ Christopher
Email
djchris@cmcvellore.ac.in
Facility Name
Primary care clinics (Shalom/LCC, CHAD)
City
Vellore
Country
India
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
DJ Christopher
Email
djchris@cmcvellore.ac.in
Facility Name
De La Salle Medical and Health Sciences Institute
City
Dasmariñas
Country
Philippines
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Charles Yu
Email
chrlsyu@yahoo.com
Facility Name
Brooklyn Chest Hospital
City
Cape Town
Country
South Africa
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Grant Theron
Email
gtheron@sun.ac.za
Facility Name
Khayelitsha District Health Center
City
Cape Town
Country
South Africa
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Grant Theron
Email
gtheron@sun.ac.za
Facility Name
Kraaifontein Community Health Clinic
City
Cape Town
Country
South Africa
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Grant Theron
Email
gtheron@sun.ac.za
Facility Name
Scottsdene primary care clinic
City
Cape Town
Country
South Africa
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Grant Theron
Email
gtheron@sun.ac.za
Facility Name
Wallacedene primary care clinic
City
Cape Town
Country
South Africa
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Grant Theron
Email
gtheron@sun.ac.za
Facility Name
Kisenyi Health Center
City
Kampala
Country
Uganda
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
William Worodria
Email
worodria@yahoo.com
Facility Name
Mulago Outpatient Department
City
Kampala
Country
Uganda
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
William Worodria
Email
worodria@yahoo.com
Facility Name
Hanoi Lung Hospital, Outpatient departments
City
Hanoi
Country
Vietnam
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Nhung Nguyen
Email
vietnhung@yahoo.com
Facility Name
National Lung Hospital, Outpatient departments
City
Hanoi
Country
Vietnam
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Nhung Nguyen
Email
vietnhung@yahoo.com

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
17584529
Citation
Cho SN, Brennan PJ. Tuberculosis: diagnostics. Tuberculosis (Edinb). 2007 Aug;87 Suppl 1:S14-7. doi: 10.1016/j.tube.2007.05.001. Epub 2007 Jun 20.
Results Reference
background
Citation
World Health Organization. Global tuberculosis report Geneva, Switzerland: World Health Organization, 2015.
Results Reference
background
PubMed Identifier
20825313
Citation
Boehme CC, Nabeta P, Hillemann D, Nicol MP, Shenai S, Krapp F, Allen J, Tahirli R, Blakemore R, Rustomjee R, Milovic A, Jones M, O'Brien SM, Persing DH, Ruesch-Gerdes S, Gotuzzo E, Rodrigues C, Alland D, Perkins MD. Rapid molecular detection of tuberculosis and rifampin resistance. N Engl J Med. 2010 Sep 9;363(11):1005-15. doi: 10.1056/NEJMoa0907847. Epub 2010 Sep 1.
Results Reference
background
PubMed Identifier
24172543
Citation
Walusimbi S, Bwanga F, De Costa A, Haile M, Joloba M, Hoffner S. Meta-analysis to compare the accuracy of GeneXpert, MODS and the WHO 2007 algorithm for diagnosis of smear-negative pulmonary tuberculosis. BMC Infect Dis. 2013 Oct 30;13:507. doi: 10.1186/1471-2334-13-507.
Results Reference
background
Citation
World Health Organization. Rapid Implementation of the Xpert MTB / RIF diagnostic test. Technical and operational 'how-to' practical considerations. Geneva, Switzerland, 2011.
Results Reference
background
PubMed Identifier
25996015
Citation
Systematic Screening for Active Tuberculosis: Principles and Recommendations. Geneva: World Health Organization; 2013. Available from http://www.ncbi.nlm.nih.gov/books/NBK294083/
Results Reference
background
Citation
World Health Organization. Drug-resistant TB. https://www.who.int/tb/areas-of-work/drug-resistant-tb/en/.
Results Reference
background
PubMed Identifier
22938757
Citation
Dalton T, Cegielski P, Akksilp S, Asencios L, Campos Caoili J, Cho SN, Erokhin VV, Ershova J, Gler MT, Kazennyy BY, Kim HJ, Kliiman K, Kurbatova E, Kvasnovsky C, Leimane V, van der Walt M, Via LE, Volchenkov GV, Yagui MA, Kang H; Global PETTS Investigators; Akksilp R, Sitti W, Wattanaamornkiet W, Andreevskaya SN, Chernousova LN, Demikhova OV, Larionova EE, Smirnova TG, Vasilieva IA, Vorobyeva AV, Barry CE 3rd, Cai Y, Shamputa IC, Bayona J, Contreras C, Bonilla C, Jave O, Brand J, Lancaster J, Odendaal R, Chen MP, Diem L, Metchock B, Tan K, Taylor A, Wolfgang M, Cho E, Eum SY, Kwak HK, Lee J, Lee J, Min S, Degtyareva I, Nemtsova ES, Khorosheva T, Kyryanova EV, Egos G, Perez MT, Tupasi T, Hwang SH, Kim CK, Kim SY, Lee HJ, Kuksa L, Norvaisha I, Skenders G, Sture I, Kummik T, Kuznetsova T, Somova T, Levina K, Pariona G, Yale G, Suarez C, Valencia E, Viiklepp P. Prevalence of and risk factors for resistance to second-line drugs in people with multidrug-resistant tuberculosis in eight countries: a prospective cohort study. Lancet. 2012 Oct 20;380(9851):1406-17. doi: 10.1016/S0140-6736(12)60734-X. Epub 2012 Aug 30. Erratum In: Lancet. 2012 Oct 20;380(9851):1386.
Results Reference
background
PubMed Identifier
17084757
Citation
Gandhi NR, Moll A, Sturm AW, Pawinski R, Govender T, Lalloo U, Zeller K, Andrews J, Friedland G. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet. 2006 Nov 4;368(9547):1575-80. doi: 10.1016/S0140-6736(06)69573-1.
Results Reference
background
PubMed Identifier
16941364
Citation
Masjedi MR, Farnia P, Sorooch S, Pooramiri MV, Mansoori SD, Zarifi AZ, Akbarvelayati A, Hoffner S. Extensively drug-resistant tuberculosis: 2 years of surveillance in Iran. Clin Infect Dis. 2006 Oct 1;43(7):841-7. doi: 10.1086/507542. Epub 2006 Aug 21.
Results Reference
background
PubMed Identifier
28749390
Citation
Prasad R, Singh A, Balasubramanian V, Gupta N. Extensively drug-resistant tuberculosis in India: Current evidence on diagnosis & management. Indian J Med Res. 2017 Mar;145(3):271-293. doi: 10.4103/ijmr.IJMR_177_16.
Results Reference
background
PubMed Identifier
30823972
Citation
Yoon C, Dowdy DW, Esmail H, MacPherson P, Schumacher SG. Screening for tuberculosis: time to move beyond symptoms. Lancet Respir Med. 2019 Mar;7(3):202-204. doi: 10.1016/S2213-2600(19)30039-6. No abstract available.
Results Reference
background
Citation
Organization WH. High-priority target product profiles for new tuberculosis diagnostics: report of a consensus meeting. Geneva, Switzerland: WHO Press; 2014. p. 98.
Results Reference
background
Citation
World Health Organization. High-priority target product profiles for new tuberculosis diagnostics: report of a consensus meeting. Geneva, Switzerland, 2014.
Results Reference
background
Citation
UNITAID. TB Diagnostics Market in Select High-Burden Countries: Current Market and Future Opportunities for Novel Diagnostics. Geneva, Switzerland, 2015.
Results Reference
background
PubMed Identifier
27780217
Citation
Subbaraman R, Nathavitharana RR, Satyanarayana S, Pai M, Thomas BE, Chadha VK, Rade K, Swaminathan S, Mayer KH. The Tuberculosis Cascade of Care in India's Public Sector: A Systematic Review and Meta-analysis. PLoS Med. 2016 Oct 25;13(10):e1002149. doi: 10.1371/journal.pmed.1002149. eCollection 2016 Oct.
Results Reference
background
PubMed Identifier
26910495
Citation
Farhat MR, Sultana R, Iartchouk O, Bozeman S, Galagan J, Sisk P, Stolte C, Nebenzahl-Guimaraes H, Jacobson K, Sloutsky A, Kaur D, Posey J, Kreiswirth BN, Kurepina N, Rigouts L, Streicher EM, Victor TC, Warren RM, van Soolingen D, Murray M. Genetic Determinants of Drug Resistance in Mycobacterium tuberculosis and Their Diagnostic Value. Am J Respir Crit Care Med. 2016 Sep 1;194(5):621-30. doi: 10.1164/rccm.201510-2091OC.
Results Reference
background
PubMed Identifier
30420247
Citation
Lange C, Chesov D, Furin J, Udwadia Z, Dheda K. Revising the definition of extensively drug-resistant tuberculosis. Lancet Respir Med. 2018 Dec;6(12):893-895. doi: 10.1016/S2213-2600(18)30428-4. Epub 2018 Nov 9. No abstract available.
Results Reference
background
PubMed Identifier
30342828
Citation
Makhado NA, Matabane E, Faccin M, Pincon C, Jouet A, Boutachkourt F, Goeminne L, Gaudin C, Maphalala G, Beckert P, Niemann S, Delvenne JC, Delmee M, Razwiedani L, Nchabeleng M, Supply P, de Jong BC, Andre E. Outbreak of multidrug-resistant tuberculosis in South Africa undetected by WHO-endorsed commercial tests: an observational study. Lancet Infect Dis. 2018 Dec;18(12):1350-1359. doi: 10.1016/S1473-3099(18)30496-1. Epub 2018 Oct 18.
Results Reference
background
PubMed Identifier
29237757
Citation
Paris L, Magni R, Zaidi F, Araujo R, Saini N, Harpole M, Coronel J, Kirwan DE, Steinberg H, Gilman RH, Petricoin EF 3rd, Nisini R, Luchini A, Liotta L. Urine lipoarabinomannan glycan in HIV-negative patients with pulmonary tuberculosis correlates with disease severity. Sci Transl Med. 2017 Dec 13;9(420):eaal2807. doi: 10.1126/scitranslmed.aal2807.
Results Reference
background
PubMed Identifier
30913250
Citation
Wood A, Barizuddin S, Darr CM, Mathai CJ, Ball A, Minch K, Somoskovi A, Hamasur B, Connelly JT, Weigl B, Andama A, Cattamanchi A, Gangopadhyay K, Bok S, Gangopadhyay S. Ultrasensitive detection of lipoarabinomannan with plasmonic grating biosensors in clinical samples of HIV negative patients with tuberculosis. PLoS One. 2019 Mar 26;14(3):e0214161. doi: 10.1371/journal.pone.0214161. eCollection 2019.
Results Reference
background
PubMed Identifier
24789953
Citation
Nakhleh MK, Jeries R, Gharra A, Binder A, Broza YY, Pascoe M, Dheda K, Haick H. Detecting active pulmonary tuberculosis with a breath test using nanomaterial-based sensors. Eur Respir J. 2014 May;43(5):1522-5. doi: 10.1183/09031936.00019114. No abstract available.
Results Reference
background
PubMed Identifier
30404942
Citation
Fernandez-Carballo BL, Broger T, Wyss R, Banaei N, Denkinger CM. Toward the Development of a Circulating Free DNA-Based In Vitro Diagnostic Test for Infectious Diseases: a Review of Evidence for Tuberculosis. J Clin Microbiol. 2019 Mar 28;57(4):e01234-18. doi: 10.1128/JCM.01234-18. Print 2019 Apr.
Results Reference
background
PubMed Identifier
28705949
Citation
Ahmad Khan F, Pande T, Tessema B, Song R, Benedetti A, Pai M, Lonnroth K, Denkinger CM. Computer-aided reading of tuberculosis chest radiography: moving the research agenda forward to inform policy. Eur Respir J. 2017 Jul 13;50(1):1700953. doi: 10.1183/13993003.00953-2017. Print 2017 Jul. No abstract available.
Results Reference
background
PubMed Identifier
25185458
Citation
Portevin D, Moukambi F, Clowes P, Bauer A, Chachage M, Ntinginya NE, Mfinanga E, Said K, Haraka F, Rachow A, Saathoff E, Mpina M, Jugheli L, Lwilla F, Marais BJ, Hoelscher M, Daubenberger C, Reither K, Geldmacher C. Assessment of the novel T-cell activation marker-tuberculosis assay for diagnosis of active tuberculosis in children: a prospective proof-of-concept study. Lancet Infect Dis. 2014 Oct;14(10):931-8. doi: 10.1016/S1473-3099(14)70884-9. Epub 2014 Aug 31.
Results Reference
background
PubMed Identifier
28847636
Citation
Yoon C, Semitala FC, Atuhumuza E, Katende J, Mwebe S, Asege L, Armstrong DT, Andama AO, Dowdy DW, Davis JL, Huang L, Kamya M, Cattamanchi A. Point-of-care C-reactive protein-based tuberculosis screening for people living with HIV: a diagnostic accuracy study. Lancet Infect Dis. 2017 Dec;17(12):1285-1292. doi: 10.1016/S1473-3099(17)30488-7. Epub 2017 Aug 25.
Results Reference
background
Citation
Schmidt S. Bringing cheap and accurate tuberculosis tests to Africa. University of Wisconsin - News. 2018.
Results Reference
background
PubMed Identifier
30541931
Citation
Luabeya AK, Wood RC, Shenje J, Filander E, Ontong C, Mabwe S, Africa H, Nguyen FK, Olson A, Weigel KM, Jones-Engel L, Hatherill M, Cangelosi GA. Noninvasive Detection of Tuberculosis by Oral Swab Analysis. J Clin Microbiol. 2019 Feb 27;57(3):e01847-18. doi: 10.1128/JCM.01847-18. Print 2019 Mar.
Results Reference
background
PubMed Identifier
31221195
Citation
Mesman AW, Calderon R, Soto M, Coit J, Aliaga J, Mendoza M, Franke MF. Mycobacterium tuberculosis detection from oral swabs with Xpert MTB/RIF ULTRA: a pilot study. BMC Res Notes. 2019 Jun 20;12(1):349. doi: 10.1186/s13104-019-4385-y.
Results Reference
background
PubMed Identifier
29348166
Citation
Liu C, Lyon CJ, Bu Y, Deng Z, Walters E, Li Y, Zhang L, Hesseling AC, Graviss EA, Hu Y. Clinical Evaluation of a Blood Assay to Diagnose Paucibacillary Tuberculosis via Bacterial Antigens. Clin Chem. 2018 May;64(5):791-800. doi: 10.1373/clinchem.2017.273698. Epub 2018 Jan 18.
Results Reference
background
PubMed Identifier
26116186
Citation
Walker TM, Kohl TA, Omar SV, Hedge J, Del Ojo Elias C, Bradley P, Iqbal Z, Feuerriegel S, Niehaus KE, Wilson DJ, Clifton DA, Kapatai G, Ip CLC, Bowden R, Drobniewski FA, Allix-Beguec C, Gaudin C, Parkhill J, Diel R, Supply P, Crook DW, Smith EG, Walker AS, Ismail N, Niemann S, Peto TEA; Modernizing Medical Microbiology (MMM) Informatics Group. Whole-genome sequencing for prediction of Mycobacterium tuberculosis drug susceptibility and resistance: a retrospective cohort study. Lancet Infect Dis. 2015 Oct;15(10):1193-1202. doi: 10.1016/S1473-3099(15)00062-6. Epub 2015 Jun 23. Erratum In: Lancet Infect Dis. 2017 Nov 21;:
Results Reference
background
PubMed Identifier
31039166
Citation
Colman RE, Mace A, Seifert M, Hetzel J, Mshaiel H, Suresh A, Lemmer D, Engelthaler DM, Catanzaro DG, Young AG, Denkinger CM, Rodwell TC. Whole-genome and targeted sequencing of drug-resistant Mycobacterium tuberculosis on the iSeq100 and MiSeq: A performance, ease-of-use, and cost evaluation. PLoS Med. 2019 Apr 30;16(4):e1002794. doi: 10.1371/journal.pmed.1002794. eCollection 2019 Apr. Erratum In: PLoS Med. 2019 Jun 3;16(6):e1002823.
Results Reference
background
PubMed Identifier
31141643
Citation
de Vos M, Ley SD, Wiggins KB, Derendinger B, Dippenaar A, Grobbelaar M, Reuter A, Dolby T, Burns S, Schito M, Engelthaler DM, Metcalfe J, Theron G, van Rie A, Posey J, Warren R, Cox H. Bedaquiline Microheteroresistance after Cessation of Tuberculosis Treatment. N Engl J Med. 2019 May 30;380(22):2178-2180. doi: 10.1056/NEJMc1815121. No abstract available.
Results Reference
background
PubMed Identifier
30085153
Citation
Shin SS, Modongo C, Baik Y, Allender C, Lemmer D, Colman RE, Engelthaler DM, Warren RM, Zetola NM. Mixed Mycobacterium tuberculosis-Strain Infections Are Associated With Poor Treatment Outcomes Among Patients With Newly Diagnosed Tuberculosis, Independent of Pretreatment Heteroresistance. J Infect Dis. 2018 Nov 5;218(12):1974-1982. doi: 10.1093/infdis/jiy480.
Results Reference
background
PubMed Identifier
25970423
Citation
Colman RE, Schupp JM, Hicks ND, Smith DE, Buchhagen JL, Valafar F, Crudu V, Romancenco E, Noroc E, Jackson L, Catanzaro DG, Rodwell TC, Catanzaro A, Keim P, Engelthaler DM. Detection of Low-Level Mixed-Population Drug Resistance in Mycobacterium tuberculosis Using High Fidelity Amplicon Sequencing. PLoS One. 2015 May 13;10(5):e0126626. doi: 10.1371/journal.pone.0126626. eCollection 2015.
Results Reference
background
PubMed Identifier
28893776
Citation
Metcalfe JZ, Streicher E, Theron G, Colman RE, Penaloza R, Allender C, Lemmer D, Warren RM, Engelthaler DM. Mycobacterium tuberculosis Subculture Results in Loss of Potentially Clinically Relevant Heteroresistance. Antimicrob Agents Chemother. 2017 Oct 24;61(11):e00888-17. doi: 10.1128/AAC.00888-17. Print 2017 Nov.
Results Reference
background
PubMed Identifier
15994154
Citation
Lee JJ, Feng L. Randomized phase II designs in cancer clinical trials: current status and future directions. J Clin Oncol. 2005 Jul 1;23(19):4450-7. doi: 10.1200/JCO.2005.03.197.
Results Reference
background
PubMed Identifier
7082756
Citation
Fleming TR. One-sample multiple testing procedure for phase II clinical trials. Biometrics. 1982 Mar;38(1):143-51.
Results Reference
background

Learn more about this trial

Rapid Research in Diagnostics Development for TB Network

We'll reach out to this number within 24 hrs